个人简历

学习经历:
1998.9-2003.7沈阳药科大学，药学（英语），学士
2004.5-2006.5韩国江原国立大学，药物化学，硕士
2006.8-2011.5美国田纳西大学，药物化学，博士
2011.5-2013.12美国田纳西大学，博士后

工作经历：
2003.7-2004.5中国中化集团青岛公司，医药外贸与技术助理
2006.8-2011.5美国田纳西大学，研究助理
2014.1-2015.8美国南方大学药学院，助理教授(AssistantProfessor)
2015.8-2017.8美国芝加哥州立大学药学院，助理/副教授(Assistant/AssociateProfessor)
2017.8-南方医科大学药学院，教授
主要获奖情况：
1.青年海外高层次人才项目，中组部，2017
2.“NewInvestigatorAward”，美国药学院联合会/AACP，2016
3.“DistinguishedScholaroftheYear”，美国南方大学药学院，2015
4.“Travelaward”，美国田纳西大学，2011
5.“Travelaward”，泛美色素细胞研究学会会员/PASPCR，2009
6.“BEST-KNUfellowship”韩国江原国立大学,2004
主要科研课题:
1.广东省科技厅国际合作项目：靶向维生素D受体(VDR)的激动剂作为抗癌药物的研究与开发。2019-2021，主持(PI)。
2.广东省高水平大学建设/南方医科大学高层次人才引进科研启动项目。2017-2020，主持(PI)。
3.中组部青年海外高层次人才项目。新型小分子抗癌药物的研究。2017-2022，主持(PI)。
4.美国国立卫生研究院/NIH/NIGMS,SC3,1SC3GM122599。NovelHIF1αInhibitorsfortheTreatmentofBreastCancer。2016.8-2019.7。经费总额:36万美金，主持(PI)。
5.美国药学院联合会/AACP。NewInvestigatorAward。Novel&TargetedProdrugStrategyForTheTreatmentofResistantOvarianCancer。2016.1-2016.12。经费总额:1万美金，主持(PI)。
6.美国国立卫生研究院/NIH,1S10OD016226-01A1，MassSpectrometerforSmallMoleculeDrugDevelopment。2014.1-2014.12。经费总额:30万美金，合作研究者(Co-I)。
7.美国国立卫生研究院/NIH,1S10OD010678-01，AcquisitionofaQ-TOFMassSpectrometer。2012.5-2013.4。经费总额:32万美金，合作研究者(Co-I)。
专利：
1.陈建军，程斌斌。一种含取代联苯的黄酮及其应用,CN109456284A
2.陈建军，程斌斌。一种含取代联苯的查尔酮及其应用,CN109336857A
3.陈建军，程斌斌。一种含取代联苯的萘及其应用,CN109438263A
4.陈建军，程斌斌。一种间苯二酚二苯甲醚及其应用,CN109503546A.
5.陈建军，李玲，吕琳，全东令。一种咪唑衍生物及其用途,CN109438358A/CN109438249A
6.陈建军，李玲，吕琳，全东令。一种苯甲酸生物及其用途,201811461871.0
7.陈建军，李刚，邓欣，任益昌。一种2-（吲哚-3-基）-吡啶并咪唑及其应用,中国,CN109776528A
8.陈建军，程斌斌。一种含取代联苯的间苯二酚甲醚衍生物及其用途,CN109761952A
9.陈建军，程斌斌。一种间苯二酚二苯甲醚衍生物及其用途。PCT/CN2019/091193
10.陈建军，任益昌，程斌斌。一种苯并五元杂环衍生物及其应用。201910812479.1
11.Compoundsfortreatmentofcancer.JP2016510748;US20160015688;US10022356;MX2015011713;IN2015DN08964.Wang,Jin;Chen,Jianjun;Miller,DuaneD.;Li,Wei.
12.Preparationofimidazole-containingcompoundsandanalogsusefulinthetreatmentofcancer.KR2016-7017425A3;KR2017-7006276;AU2015202828;.Miller,DuaneD.;Wei,Li;Chen,Jianjun;Dalton,JamesT.;Li,Chien-Ming;Ahn,Sunjoo.
13.Preparationofaryl-andheterocycliccompoundsfortreatmentofcanceranddrug-resistanttumors.IN201718037031.Lu,Yan;Li,Chien-Ming;Wang,Zhao;Chen,Jianjun;Li,Wei;Dalton,JamesT.;Miller,DuaneD.;Duke,Charles;Ahn,Sunjoo.
14.Aroylazolecompoundsasanticanceragentsandtheirpreparationandusefortreatmentofcancersanddrugresistantcancers.US20180093971.Lu,Yan;Li,Chien-Ming;Wang,Zhao;Chen,Jianjun;Li,Wei;Dalton,JamesT.;Miller,DuaneD.;Duke,Charles;Ahn,Sunjoo.
15.Preparationofaryl-andheterocycliccompoundsfortreatmentofcanceranddrug-resistanttumors.JP2017008091.Dalton,JamesT.;Miller,DuaneD.;Ahn,Sunjoo;Chen,Jianjun;Duke,Charles;Li,Chien-Ming;Li,Wei;Lu,Yan;Wang,Zhao.
16.Enzymaticproductionorchemicalsynthesisandusesforandrosta-5,7-dienesorpregna-5,7-dienesandUVBconversionproductsthereof.US20140200201.Zjawiony,JordanK.;Li,Wei;Zbytek,Blazej;Tuckey,RobertC.;ZjawionyJordan,K.;Nguyen,MinhNgoc;Zmijewski,MichalA.;Janjetovic,Zorica;Sweatman,TrevorW.;Miller,DuaneD.;Chen,Jianjun.
17.Preparationofazolecompoundsfortreatmentofcancer.IN201718037031.Miller,DuaneD.;Li,Wei;Wang,Zhao;Lu,Yan;Chen,Jianjun;Dalton,JamesT.;Li,Chien-Ming.
18.Azolesandrelatedcompoundsfortreatmentofcancerandtheirpreparation.US20170226086;Li,Wei;Xiao,Mi;Dalton,James;Ahn,Sunjoo;Miller,DuaneD.;Chen,Jianjun;Wang,Jin.
19.Compoundsfortreatmentofcancer.WO2014138279;AU2014225761;KR2015123328.ByWang,Jin;Chen,Jianjun;Miller,DuaneD.;Li,Wei.
20.Preparationofazolecompoundsfortreatmentofcancer.US12/485,881.Miller,DuaneD.;Li,Wei;Wang,Zhao;Lu,Yan;Chen,Jianjun;Dalton,JamesT.;Li,Chien-Ming.
21.Enzymaticproductionorchemicalsynthesisandusesforandrosta-5,7-dienesorpregna-5,7-dienesandUVBconversionproductsthereof.US12/807,178.AndrzejT.Slominski.;Li,Wei;Zbytek,Blazej;Tuckey,RobertC.;ZjawionyJordan,K.;Nguyen,MinhNgoc;ZmijewsklMichal,A.;Janjetovic,Zorica;SweatmanTrevor,W.;Miller,DuaneD.;Chen,Jianjun,Postlethwaite,ArnoldE.
22.Design,synthesisandbiologicalstudiesofanewclassofcytotoxicagents,2-arylthiazolidine-4-carboxylicacidamidesforprostatecancer,2014.US7,307,093;US7,662,842;US8,592,465;Mexico262836;Japan5507552;RussianFederation2514427.JianjunChen,JamesDalton,DukeCharles,DongjinHwang,WeiLi,Chien-MingLi,YanLu,DuaneMiller,ZhaoWang.

研究领域

研究方向：
1.新型抗癌小分子药物的合成及体内外活性研究
2.新药筛选/研发计算机辅助药物设计合成药物化学

近期论文

论文发表:
1.LingLi#,DonglingQuan#,JingxuanChen,JiahaoDing,JinwuZhao,LinLv*,JianjunChen*.Design,synthesis,andbiologicalevaluationof1-substituted-2-arylimidazolestargetingtubulinpolymerizationaspotentialanticanceragents.EurJMedChem.,2019,Sep26,184:111732.
2.HaoCao#,LingLi#,DeyingYang,LimingZeng,YeweiXie,BinYu*,GuochaoLiao*,JianjunChen*,RecentProgressinHistoneMethyltransferase(G9a)InhibitorsasAnticancerAgents.EurJMedChem.,2019Jun28,179:537-546.
3.JingxuanChen,SiboJiang,JinWang,JwalaRenukuntla,SumanSirimullaandJianjunChen*.AComprehensiveReviewofCytochromeP4502E1forXenobioticMetabolism.DrugMetabolismReviews.2019May,51(2):178-195.
4.XiaopengPeng,GuochaoLiao,PinghuaSun,ZhiqiangYu,JianjunChen*,AnoverviewofHDACinhibitorsandtheirsyntheticroutes.CurrentTopicsinMedicinalChemistry,2019,19(12):1005-1040.
5.Wu,Peng;Wang,Xuefeng;Wang,Zigui;Ma,Wen;Guo,Jinshan;Chen,Jianjun;Yu,Zhiqiang;Li,Jizhen;Zhou,Dongfang.Light-ActivatableProdrugandAIEgenCopolymerNanoparticleforDual-DrugMonitoringandCombinationTherapy.ACSApplMaterInterfaces.2019May22,11(20):18691-18700.
6.BinbinCheng,Wei-EnYuan,JingSu,YaoLiu,JianjunChen*,RecentAdvancesinSmallMoleculebasedCancerImmunotherapy,EurJMedChem.,2018,157:582-598.
7.XiaoxunLi,PeterD.Livant,JianjunChen*,Analkene-formingcascadereactionenrouteto2,2'-bi(glycerol),SynLett,2018,29(13):1769-1772.
8.LingLi,SiboJiang,XiaoxunLi,YaoLiu,JingSu,JianjunChen*,Recentadvancesintrimethoxyphenyl(TMP)basedtubulininhibitorstargetingthecolchicinebindingsite,EurJMedChem.,2018,151,482-494.
9.XiaoshuangGuo;YuanCheng;XiaotianZhao;YanliLuo;JianjunChen*;Wei-EnYuan*,Advancesinredox-responsivedrugdeliverysystemsoftumormicroenvironment,JournalofNanobiotechnology,2018,16(1):74.doi:10.1186/s12951-018-0398-2.
10.SiboJiang,YeseniaLFranco,YanZhou,JianjunChen*,NanotechnologyinRetinalDrugDelivery,InternationalJournalofOphthalmology,2018,11(6),1038-1044.
11.ZhongyaoCheng,YumeiLian,ZulKamal,XinMa,JianjunChen,XinboZhou*,JingSu*,MingfengQiu*.NanocrystalsTechnologyforPharmaceuticalScience.CurrPharmDes.2018,24(21):2497-2507.
12.XiaomingLi,XiaoshuangGuo,YuanCheng,XiaotianZhao,ZhiweiFang,YanliLuo,ShujunXia,YunFeng,JianjunChen*,Wei-enYuan*.pH-responsivecross-linkedlowmolecularweightpolyethylenimineasanefficientgenevectorfordeliveryofplasmidDNAencodinganti-VEGF-shRNAfortumortreatment.FrontiersinOncology,2018Sep25;8:354.
13.WangBin,YuLiu,LianyanHuang,JianjunChen,JingJingLi,RuishanWang,DehnaM.Fong,CarlesJusticia,AnnaPlanas,DeborahYoung,WeiLi,MichaelP.McDonald,RuihongChen&Francesca-FangLiao,“ACNS-permeableHsp90inhibitorrescuessynapticdysfunctionandmemorylossinAlzheimer’smiceviaHSF-1mediatedmechanism”,MolecularPsychiatry.2017,22(7):990–1001.
14.XuelanTang,PingLu,MingfengQiu,JianjunChen,JingSheng,JingSu,“ScreeningPEGylatedPolyethylenimineDerivativesforSafeandEfficientDeliveryofGeneMaterials”,EurJPharmSci.2017,96:115-128.
15.JianjunChen*,ReviewofDesignofPrecursorsforSustainableChemistry,JournalofNaturalProducts,2017,80(5),1701–1702.
16.YananSun,JingSu,GeyiLiu,JianjunChen,XiumeiZhang,RanZhang,MinhanJiang,MingfengQiu,“Advancesofbloodcell-baseddrugdeliverysystems”,RSCAdv.,2016,6,106316–106326.
17.Chuan-LingSi,Xiao-FengHuang,Liang-LiangAn,Cui-YunLiu,SuFan,Dan-NiXie,Yi-MeiHong,JianjunChen*.“ExtractionandStructuralCharacterizationofFlavonoidsfromTwigsofSophorajaponica”.BioResources,2015,10(4),8397-8404.
18.ParkHaeil,Chuan-LingSi,JianjunChen*.“TotalSynthesisofAmentoflavone”.MedicinalChemistry,2015,5(11),467-469.
19.ElaineW.Tieu,WeiLi,JianjunChen,Tae-KangKim,DejianMa,AndrzejT.Slominski,andRobertC.Tuckey,“Metabolismof20-hydroxyvitaminD3and20,23-dihydroxyvitaminD3byratandhumanCYP24A1”,JournalofSteroidBiochemistryandMolecularBiology,2015,149,153–165.
20.GeorginaN.Masoud,JinWang,JianjunChen,DuaneMiller,WeiLi.“Design,SynthesisandBiologicalEvaluationofNovelHIF-1αInhibitors”.AnticancerResearch,2015,35(7):3849-59.
21.JianjunChen,JinWang,Tae-KangKim,ElaineWTieu,EdithTang,ZongtaoLin,DianneKovacic,DuaneDMiller,ArnoldPostlethwaite,RobertTuckey,AndrzejTSlominski,WeiLi,“NovelVitaminDAnalogsasPotentialTherapeutics:Metabolism,ToxicityProfiling,andAntiproliferativeActivity”,AnticancerResearch,2014,34(5),2153-2163.
22.JianjunChen,JinWang,LucianaP.Schwab,Kyung-TaePark,TiffanyNSeagroves,LisaK.Jennings,DuaneD.Miller,WeiLi.“Benzimidazoleanalogsaspotenthypoxiainduciblefactorinhibitors:synthesis,biologicalevaluation,andprofilingdrug-likeproperties”,AnticancerResearch,2014,34(8)3891-3904.
23.JinWang,JianjunChen,DuaneD.MillerandWeiLi,“SynergisticCombinationsofNovelTubulinInhibitorsandVemurafenibOvercomeVemurafenibAcquiredResistanceinBRAFV600EMelanoma”,MolecularCancerTherapeutics,2014,13,16-26.
24.YanLu,JianjunChen,JinWang,Chien-MingLi,SunjooAhn,ChristinaM.Barrett,JamesT.Dalton,WeiLi,DuaneD.Miller,“Design,Synthesis,MolecularModeling,andBiologicalEvaluationofNovelColchicineBindingSiteTubulinInhibitorsasPotentialAnticancerAgents”,JournalofMedicinalChemistry,2014,57(17),7355–7366.
25.RobertC.Tuckey,AndrzejT.Slominski,ChloeY.S.Cheng,JianjunChen,Tae-KangKim,MinXiaoandWeiLi.“LumisterolismetabolizedbyCYP11A1:discoveryofanewpathway”,TheInternationalJournalofBiochemistry&CellBiology,2014,55,24-34.
26.JianjunChen,AndrzejT.Slominski,DuaneD.Miller,WeiLi.“EffectsofsidechainlengthandcompositiononthekineticconversionandproductdistributionofvitaminD3analogsdeterminedbyreal-timeNMR”,Dermato-Endocrinology,2013,5,142-149.
27.AndrzejT.Slominski,Tae-KangKim,MichalA.Zmijewski,ZoricaJanjetovic,WeiLi,JianjunChen,EkaterinaI.Kusniatsova,IgorSemak,ArnoldPostlethwaite,DuaneD.Miller,JordanK.Zjawiony,RobertC.Tuckey.“NovelvitaminDphotoproductsandtheirprecursorsintheskin”,Dermato-Endocrinology,2013,5,8-19.
28.EdithK.Y.Tang,JianjunChen,ZoricaJanjetovic,ElaineW.Tieu,AndrzejT.Slominski,WeiLiandRobertC.Tuckey.“HydroxylationofCYP11A1-derivedproductsofvitaminD3metabolismbyhumanandmouseCYP27B1”,DrugMetabolismandDisposition,2013,41,1112-1124.
29.HovigKouyoumdjian;DavidC.Zhu;MohammadH.El-Dakdouki;KellyLorenz;JianjunChen;WeiLi;XuefeiHuang.“GlyconanoparticleAidedDetectionofβ-AmyloidbyMagneticResonanceImagingandAttenuationofβ-AmyloidInducedCytotoxicity”,ACSChemicalNeuroscience,2013,4,575-584.
30.MinXiao,SunjooAhn,JinWang,JianjunChen,DuaneMiller,JamesDalton,WeiLi.“Discoveryof4-Aryl-2-benzoyl-imidazolesAsTubulinPolymerizationInhibitorwithPotentAntiproliferativeProperties”,JournalofMedicinalChemistry,2013,56,3318–3329.
31.JianjunChen,SunjooAhn,JinWang,YanLu,JamesT.Dalton,DuaneD.Miller,WeiLi,“Discoveryofnovel2-aryl-4-benzoyl-imidazole(ABI-III)analoguestargetingtubulinpolymerizationasantiproliferativeagents”,JournalofMedicinalChemistry,2012,55,7285-7289(本文首次报道的化合物已转让给美国VeruPharm公司,2019年开始在美国进行临床I/II期试验，治疗晚期前列腺癌；化合物代号:VERU-111;ClinicalTrials.govIdentifier:NCT03752099).
32.YanLu,JianjunChen,ZoricaJanjetovic,PhillipMichaels,EdithKYTang,Jinwang,RobertC.Tuckey,AndrzejT.Slominski,WeiLi,DuaneD.Miller,\
主要学术任职：
1.广东省药学会-药物化学专业委员会委员
2.美国制药科学家协会(AAPS)会员
3.美国药学院联合会(AACP)会员
4.美国癌症协会(AACR)会员
5.美国化学会(ACS)会员